Physician

Deepnarayan Tiwarri, M.D.

According to 2025 Medicare claims, Deepnarayan Tiwarri, M.D. (NPI: 1649217464) practices hematology/oncology in the Washington, DC-MD market, with the plurality of this provider's patient population coming from Prince Georges, MD. This provider's primary affiliated billing organization is MARYLAND ONCOLOGY HEMATOLOGY, P.A. (NPI: 1821271032; TIN: 113652573) and primary practice location at 20613-3045.

Tiwarri's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,192 traditional Medicare patients, billed 240,142 HCPCS/CPT codes, and received $3,740,172 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 826 prescription claims across 196 beneficiaries totaling $2,282,059 in drug costs, led by Ibrance (Palbociclib). DME data shows 216 claims. Open Payments data shows 87 records totaling $5,009. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $1,383,244 to $3,740,172. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $603,209 to $2,282,059. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$2.5M$5.0M2015 Medicare payment: $1,383,244 (USD; Tot_Mdcr_Pymt_Amt)2016 Medicare payment: $1,664,371 (USD; Tot_Mdcr_Pymt_Amt)2017 Medicare payment: $2,272,746 (USD; Tot_Mdcr_Pymt_Amt)2018 Medicare payment: $3,050,104 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $3,354,521 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $4,510,086 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $4,987,905 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $4,648,352 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $4,966,870 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $3,740,172 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
2015894151,027$1,383,244
2016996163,305$1,664,371
20171,074212,337$2,272,746
20181,182272,769$3,050,104
20191,096350,658$3,354,521
20201,142431,003$4,510,086
20211,179491,230$4,987,905
20221,286469,770$4,648,352
20231,233427,804$4,966,870
20241,192240,142$3,740,172

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$1.2M$2.5M2015 Drug cost: $603,209 (USD; Tot_Drug_Cst)2016 Drug cost: $527,059 (USD; Tot_Drug_Cst)2017 Drug cost: $657,356 (USD; Tot_Drug_Cst)2018 Drug cost: $1,361,071 (USD; Tot_Drug_Cst)2019 Drug cost: $1,598,829 (USD; Tot_Drug_Cst)2020 Drug cost: $1,716,659 (USD; Tot_Drug_Cst)2021 Drug cost: $2,060,514 (USD; Tot_Drug_Cst)2022 Drug cost: $1,912,270 (USD; Tot_Drug_Cst)2023 Drug cost: $2,457,705 (USD; Tot_Drug_Cst)2024 Drug cost: $2,282,059 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
2015134463$603,209
2016129553$527,059
2017136665$657,356
2018143757$1,361,071
2019125676$1,598,829
2020141676$1,716,659
2021141725$2,060,514
2022142644$1,912,270
2023147651$2,457,705
2024196826$2,282,059

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

DME Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: DME_Suplr_Mdcr_Pymt_Amt. Source: Medicare DME, Devices & Supplies by Referring Provider.0$7.7K$15K2015 Medicare payment: $13,803 (USD; DME_Suplr_Mdcr_Pymt_Amt)2016 Medicare payment: $15,492 (USD; DME_Suplr_Mdcr_Pymt_Amt)2017 Medicare payment: $10,641 (USD; DME_Suplr_Mdcr_Pymt_Amt)2019 Medicare payment: $3,728 (USD; DME_Suplr_Mdcr_Pymt_Amt)2020 Medicare payment: $6,366 (USD; DME_Suplr_Mdcr_Pymt_Amt)2021 Medicare payment: $6,919 (USD; DME_Suplr_Mdcr_Pymt_Amt)2022 Medicare payment: $2,833 (USD; DME_Suplr_Mdcr_Pymt_Amt)2023 Medicare payment: $15,115 (USD; DME_Suplr_Mdcr_Pymt_Amt)2024 Medicare payment: $5,240 (USD; DME_Suplr_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClaimsPayment
2015N/R29$13,803
2016N/R50$15,492
2017N/R68$10,641
2018N/RN/RN/R
2019N/R32$3,728
20201298$6,366
2021N/R129$6,919
2022N/R108$2,833
2023N/R139$15,115
2024N/R216$5,240

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
99214Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more6601,188$109
80053Blood test, comprehensive group of blood chemicals8042,526$10
83550Iron binding capacity5531,332$9
85025Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count8173,207$8
83540Iron level5531,329$6

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
IbrancePalbociclib20560$322,552
RevlimidLenalidomide18504$296,669
PomalystPomalidomide13364$199,769
TasignaNilotinib Hcl16448$188,725
ImbruvicaIbrutinib11308$178,574

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS CodeHCPCS DescriptionSupplier Rental IndicatorTotal Supplier BeneficiariesTotal Supplier ClaimsTotal Medicare Payment Amount
J8521Capecitabine, oral, 500 mgNN/R68$1,767
J8700Temozolomide, oral, 5 mgNN/R20$1,299
Q0511Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day periodNN/R50$903
Q0512Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day periodNN/R57$715
J8999Prescription drug, oral, chemotherapeutic, nosNN/R21$557

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.86$2,054PFIZER INC.
Research PaymentsReported research-related payment or transfer-of-value amount.1$2,955SANOFI US SERVICES INC.
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Deepnarayan Tiwarri, M.D.?

Tedicare shows public-source Medicare data for Deepnarayan Tiwarri, M.D. (NPI 1649217464), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Deepnarayan Tiwarri, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Deepnarayan Tiwarri, M.D.?

Deepnarayan Tiwarri, M.D. is linked to MARYLAND ONCOLOGY HEMATOLOGY, P.A. (billing NPI 1821271032) in the available physician profile data.

Does Deepnarayan Tiwarri, M.D. have Open Payments data?

Deepnarayan Tiwarri, M.D. has 87 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.